316 related articles for article (PubMed ID: 29106987)
1. Targeting interferons as a strategy for systemic sclerosis treatment.
Ciechomska M; Skalska U
Immunol Lett; 2018 Mar; 195():45-54. PubMed ID: 29106987
[TBL] [Abstract][Full Text] [Related]
2. Type I interferon dysregulation in Systemic Sclerosis.
Skaug B; Assassi S
Cytokine; 2020 Aug; 132():154635. PubMed ID: 30685202
[TBL] [Abstract][Full Text] [Related]
3. Interferons and scleroderma-a new clue to understanding the pathogenesis of scleroderma?
Coelho LF; de Oliveira JG; Kroon EG
Immunol Lett; 2008 Jun; 118(2):110-5. PubMed ID: 18499269
[TBL] [Abstract][Full Text] [Related]
4. The role of type 1 interferon in systemic sclerosis.
Wu M; Assassi S
Front Immunol; 2013 Sep; 4():266. PubMed ID: 24046769
[TBL] [Abstract][Full Text] [Related]
5. Pathogenesis of systemic sclerosis-current concept and emerging treatments.
Furue M; Mitoma C; Mitoma H; Tsuji G; Chiba T; Nakahara T; Uchi H; Kadono T
Immunol Res; 2017 Aug; 65(4):790-797. PubMed ID: 28488090
[TBL] [Abstract][Full Text] [Related]
6. Type I IFNs Regulate Inflammation, Vasculopathy, and Fibrosis in Chronic Cutaneous Graft-versus-Host Disease.
Delaney TA; Morehouse C; Brohawn PZ; Groves C; Colonna M; Yao Y; Sanjuan M; Coyle AJ
J Immunol; 2016 Jul; 197(1):42-50. PubMed ID: 27226090
[TBL] [Abstract][Full Text] [Related]
7. Role of type I interferons and innate immunity in systemic sclerosis: unbalanced activities on distinct cell types?
Barrat FJ; Lu TT
Curr Opin Rheumatol; 2019 Nov; 31(6):569-575. PubMed ID: 31436583
[TBL] [Abstract][Full Text] [Related]
8. New developments in the pathogenesis of systemic sclerosis.
Sakkas LI
Autoimmunity; 2005 Mar; 38(2):113-6. PubMed ID: 16040330
[TBL] [Abstract][Full Text] [Related]
9. The interferon type I signature is present in systemic sclerosis before overt fibrosis and might contribute to its pathogenesis through high BAFF gene expression and high collagen synthesis.
Brkic Z; van Bon L; Cossu M; van Helden-Meeuwsen CG; Vonk MC; Knaapen H; van den Berg W; Dalm VA; Van Daele PL; Severino A; Maria NI; Guillen S; Dik WA; Beretta L; Versnel MA; Radstake T
Ann Rheum Dis; 2016 Aug; 75(8):1567-73. PubMed ID: 26371289
[TBL] [Abstract][Full Text] [Related]
10. Early inflammatory players in cutanous fibrosis.
Raker V; Haub J; Stojanovic A; Cerwenka A; Schuppan D; Steinbrink K
J Dermatol Sci; 2017 Sep; 87(3):228-235. PubMed ID: 28655471
[TBL] [Abstract][Full Text] [Related]
11. Pathogenic roles of B lymphocytes in systemic sclerosis.
Yoshizaki A
Immunol Lett; 2018 Mar; 195():76-82. PubMed ID: 29307688
[TBL] [Abstract][Full Text] [Related]
12. [B cell abnormalities and therapeutic strategies in systemic sclerosis].
Yoshizaki A
Nihon Rinsho Meneki Gakkai Kaishi; 2016; 39(3):197-206. PubMed ID: 27320935
[TBL] [Abstract][Full Text] [Related]
13. Role of toll-like receptors in systemic sclerosis.
Ciechomska M; Cant R; Finnigan J; van Laar JM; O'Reilly S
Expert Rev Mol Med; 2013 Aug; 15():e9. PubMed ID: 23985302
[TBL] [Abstract][Full Text] [Related]
14. Systemic sclerosis: a prototypic multisystem fibrotic disorder.
Varga J; Abraham D
J Clin Invest; 2007 Mar; 117(3):557-67. PubMed ID: 17332883
[TBL] [Abstract][Full Text] [Related]
15. Endogenous ligands of TLR4 promote unresolving tissue fibrosis: Implications for systemic sclerosis and its targeted therapy.
Bhattacharyya S; Varga J
Immunol Lett; 2018 Mar; 195():9-17. PubMed ID: 28964818
[TBL] [Abstract][Full Text] [Related]
16. New pathogenic and therapeutic concepts in systemic sclerosis.
Hügle T; Huigens CA; van Laar JM
Arzneimittelforschung; 2009; 59(12):615-24. PubMed ID: 20108646
[TBL] [Abstract][Full Text] [Related]
17. The role of platelets in autoimmunity, vasculopathy, and fibrosis: Implications for systemic sclerosis.
Ntelis K; Solomou EE; Sakkas L; Liossis SN; Daoussis D
Semin Arthritis Rheum; 2017 Dec; 47(3):409-417. PubMed ID: 28602360
[TBL] [Abstract][Full Text] [Related]
18. E3 ubiquitin ligase: A potential regulator in fibrosis and systemic sclerosis.
Huang XL; Zhang L; Duan Y; Wang YJ; Zhao JH; Wang J
Cell Immunol; 2016; 306-307():1-8. PubMed ID: 27406900
[TBL] [Abstract][Full Text] [Related]
19. MIG chemokine in systemic sclerosis. MIG in Systemic sclerosis.
Ragusa F
Clin Ter; 2018; 169(4):e178-e183. PubMed ID: 30151551
[TBL] [Abstract][Full Text] [Related]
20. Systemic sclerosis.
Asano Y
J Dermatol; 2018 Feb; 45(2):128-138. PubMed ID: 29226387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
